Amarin Co. plc (NASDAQ:AMRN) insider Steven B. Ketchum sold 64,683 shares of the stock in a transaction on Friday, January 5th. The stock was sold at an average price of $4.40, for a total transaction of $284,605.20. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Amarin Co. plc (NASDAQ AMRN) opened at $4.30 on Wednesday. Amarin Co. plc has a 12 month low of $2.81 and a 12 month high of $4.47. The company has a quick ratio of 1.32, a current ratio of 1.63 and a debt-to-equity ratio of -1.48. The stock has a market cap of $1,160.00, a price-to-earnings ratio of -15.93 and a beta of 0.62.

Amarin (NASDAQ:AMRN) last posted its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01. The firm had revenue of $47.10 million during the quarter, compared to analyst estimates of $45.85 million. During the same quarter in the previous year, the business posted ($0.08) earnings per share. The business’s quarterly revenue was up 45.4% compared to the same quarter last year. equities analysts anticipate that Amarin Co. plc will post -0.22 earnings per share for the current fiscal year.

A number of large investors have recently bought and sold shares of the stock. Neuberger Berman Group LLC acquired a new position in Amarin in the 3rd quarter valued at $350,000. Alkeon Capital Management LLC bought a new stake in Amarin in the 3rd quarter valued at $7,875,000. Cubist Systematic Strategies LLC bought a new stake in Amarin in the 3rd quarter valued at $226,000. University of Notre Dame DU Lac bought a new stake in Amarin in the 3rd quarter valued at $2,814,000. Finally, TD Asset Management Inc. bought a new stake in Amarin in the 3rd quarter valued at $285,000. Institutional investors and hedge funds own 40.12% of the company’s stock.

Several brokerages have recently commented on AMRN. Cantor Fitzgerald set a $10.00 price target on shares of Amarin and gave the stock a “buy” rating in a research note on Wednesday, December 6th. ValuEngine upgraded shares of Amarin from a “sell” rating to a “hold” rating in a research note on Wednesday, December 20th. BidaskClub upgraded shares of Amarin from a “sell” rating to a “hold” rating in a research note on Thursday, December 21st. Jefferies Group restated a “buy” rating on shares of Amarin in a research note on Wednesday, October 11th. Finally, Zacks Investment Research lowered shares of Amarin from a “hold” rating to a “sell” rating in a research note on Tuesday, December 12th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $7.75.

ILLEGAL ACTIVITY NOTICE: “Amarin Co. plc (AMRN) Insider Sells $284,605.20 in Stock” was published by Watch List News and is the property of of Watch List News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.watchlistnews.com/amarin-co-plc-amrn-insider-sells-284605-20-in-stock/1801018.html.

Amarin Company Profile

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.